Skip to main content
PMC home page
British Journal of Sports Medicine logoLink to British Journal of Sports Medicine
. 2004 Dec;38(6):704–708. doi: 10.1136/bjsm.2003.006635

Abnormally high serum ferritin levels among professional road cyclists

H Zotter 1, N Robinson 1, M Zorzoli 1, L Schattenberg 1, M Saugy 1, P Mangin 1
PMCID: PMC1724983  PMID: 15562163

Abstract

Background: An international, longitudinal medical follow up examination of male professional road cyclists revealed excessively elevated serum ferritin levels.

Objective: To evaluate the importance of elevated ferritin values among professional cyclists, their relationship with age and nationality, and their evolution over 3 years.

Methods: Over 1000 serum ferritin values were collected. Other parameters were included in order to exclude conditions which might have increased ferritin levels without changing body iron stores.

Results: In 1999, over 45% of riders displayed ferritin values above 300 ng/ml and one fourth levels over 500 ng/ml. These percentages had decreased to 27% and 9%, respectively, 3 years later, while the overall average, which was above the normal limits in 1999, had decreased by 33% in 3 years. Older cyclists had higher ferritin values than younger cyclists. There was also a relationship between ferritin levels and the nationality of the cyclists. Analysis of 714 riders in 2000 and 2002 showed only a slight and insignificant decrease in the mean ferritin value although those with initially elevated iron stores had a much greater decrease.

Conclusion: Professional road cyclists used excessive iron supplementation leading to high serum ferritin levels correlating with increased body iron stores. Although the situation progressively improved over 3 years, it remains worrying as increased body iron stores are related to health complications. Therefore, prevention in addition to the fight against doping should be a main goal of the UCI. Aggressive therapy for athletes with excessive ferritin values should be carried out at or before the end of their careers.

Full Text

The Full Text of this article is available as a PDF (145.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamson J. W. The relationship of erythropoietin and iron metabolism to red blood cell production in humans. Semin Oncol. 1994 Apr;21(2 Suppl 3):9–15. [PubMed] [Google Scholar]
  2. Anderson M. G., Kelly A. M. Serum ferritin by a rapid and inexpensive ELISA method. Clin Chim Acta. 1981 Nov 11;116(3):405–408. doi: 10.1016/0009-8981(81)90061-9. [DOI] [PubMed] [Google Scholar]
  3. Andrews N. C. Disorders of iron metabolism. N Engl J Med. 1999 Dec 23;341(26):1986–1995. doi: 10.1056/NEJM199912233412607. [DOI] [PubMed] [Google Scholar]
  4. Andrews N. C. Disorders of iron metabolism. N Engl J Med. 1999 Dec 23;341(26):1986–1995. doi: 10.1056/NEJM199912233412607. [DOI] [PubMed] [Google Scholar]
  5. Andrews N. C. The iron transporter DMT1. Int J Biochem Cell Biol. 1999 Oct;31(10):991–994. doi: 10.1016/s1357-2725(99)00065-5. [DOI] [PubMed] [Google Scholar]
  6. Beutler Ernest, Felitti Vincent, Ho Ngoc J., Gelbart Terri. Relationship of body iron stores to levels of serum ferritin, serum iron, unsaturated iron binding capacity and transferrin saturation in patients with iron storage disease. Acta Haematol. 2002;107(3):145–149. doi: 10.1159/000057632. [DOI] [PubMed] [Google Scholar]
  7. Conrad M. E., Umbreit J. N., Moore E. G. Iron absorption and transport. Am J Med Sci. 1999 Oct;318(4):213–229. doi: 10.1097/00000441-199910000-00002. [DOI] [PubMed] [Google Scholar]
  8. Cook J. D., Lipschitz D. A., Miles L. E., Finch C. A. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr. 1974 Jul;27(7):681–687. doi: 10.1093/ajcn/27.7.681. [DOI] [PubMed] [Google Scholar]
  9. Deugnier Yves, Loréal Olivier, Carré François, Duvallet Andŕe, Zoulim Fabien, Vinel Jean Pierre, Paris Jean Claude, Blaison Denis, Moirand Romain, Turlin Bruno. Increased body iron stores in elite road cyclists. Med Sci Sports Exerc. 2002 May;34(5):876–880. doi: 10.1097/00005768-200205000-00023. [DOI] [PubMed] [Google Scholar]
  10. Eschbach J. W., Abdulhadi M. H., Browne J. K., Delano B. G., Downing M. R., Egrie J. C., Evans R. W., Friedman E. A., Graber S. E., Haley N. R. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989 Dec 15;111(12):992–1000. doi: 10.7326/0003-4819-111-12-992. [DOI] [PubMed] [Google Scholar]
  11. Eschbach J. W., Egrie J. C., Downing M. R., Browne J. K., Adamson J. W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987 Jan 8;316(2):73–78. doi: 10.1056/NEJM198701083160203. [DOI] [PubMed] [Google Scholar]
  12. Fracanzani A. L., Conte D., Fraquelli M., Taioli E., Mattioli M., Losco A., Fargion S. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 2001 Mar;33(3):647–651. doi: 10.1053/jhep.2001.22506. [DOI] [PubMed] [Google Scholar]
  13. Gerlach M., Ben-Shachar D., Riederer P., Youdim M. B. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem. 1994 Sep;63(3):793–807. doi: 10.1046/j.1471-4159.1994.63030793.x. [DOI] [PubMed] [Google Scholar]
  14. Iacobello C., Ghielmi S., Belloli S., Arosio P., Albertini A. Use of a reference standard to improve the accuracy and precision of seven kits for determination of ferritin in serum. Clin Chem. 1984 Feb;30(2):298–301. [PubMed] [Google Scholar]
  15. Kehrer J. P. The Haber-Weiss reaction and mechanisms of toxicity. Toxicology. 2000 Aug 14;149(1):43–50. doi: 10.1016/s0300-483x(00)00231-6. [DOI] [PubMed] [Google Scholar]
  16. Kirlin L. F. Case management of the anemic patient: epoetin alfa--focus on iron supplementation. ANNA J. 1993 Dec;20(6):678–681. [PubMed] [Google Scholar]
  17. Kletzmayr Josef, Hörl Walter H. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant. 2002;17 (Suppl 2):25–29. doi: 10.1093/ndt/17.suppl_2.25. [DOI] [PubMed] [Google Scholar]
  18. Ma Jing, Stampfer Meir J. Body iron stores and coronary heart disease. Clin Chem. 2002;48(4):601–603. [PubMed] [Google Scholar]
  19. Macdougall I. C., Hutton R. D., Cavill I., Coles G. A., Williams J. D. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ. 1989 Jul 15;299(6692):157–158. doi: 10.1136/bmj.299.6692.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Major A., Mathez-Loic F., Rohling R., Gautschi K., Brugnara C. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol. 1997 Aug;98(2):292–294. doi: 10.1046/j.1365-2141.1997.2123031.x. [DOI] [PubMed] [Google Scholar]
  21. Mallory M. A., Kowdley K. V. Hereditary hemochromatosis and cancer risk: more fuel to the fire? Gastroenterology. 2001 Nov;121(5):1253–1254. doi: 10.1016/s0016-5085(01)70014-5. [DOI] [PubMed] [Google Scholar]
  22. McCord J. M. Iron, free radicals, and oxidative injury. Semin Hematol. 1998 Jan;35(1):5–12. [PubMed] [Google Scholar]
  23. Milman N., Ovesen L., Byg K., Graudal N. Iron status in Danes updated 1994. I: prevalence of iron deficiency and iron overload in 1332 men aged 40-70 years. Influence Of blood donation, alcohol intake, and iron supplementation. Ann Hematol. 1999 Sep;78(9):393–400. doi: 10.1007/s002770050537. [DOI] [PubMed] [Google Scholar]
  24. Moirand R., Mortaji A. M., Loréal O., Paillard F., Brissot P., Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet. 1997 Jan 11;349(9045):95–97. doi: 10.1016/S0140-6736(96)06034-5. [DOI] [PubMed] [Google Scholar]
  25. Newhouse I. J., Clement D. B. Iron status in athletes. An update. Sports Med. 1988 Jun;5(6):337–352. doi: 10.2165/00007256-198805060-00001. [DOI] [PubMed] [Google Scholar]
  26. Nielsen P., Nachtigall D. Iron supplementation in athletes. Current recommendations. Sports Med. 1998 Oct;26(4):207–216. doi: 10.2165/00007256-199826040-00001. [DOI] [PubMed] [Google Scholar]
  27. Parkkinen J., von Bonsdorff L., Peltonen S., Grönhagen-Riska C., Rosenlöf K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant. 2000 Nov;15(11):1827–1834. doi: 10.1093/ndt/15.11.1827. [DOI] [PubMed] [Google Scholar]
  28. Patruta S. I., Edlinger R., Sunder-Plassmann G., Hörl W. H. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol. 1998 Apr;9(4):655–663. doi: 10.1681/ASN.V94655. [DOI] [PubMed] [Google Scholar]
  29. Schumacher Yorck Olaf, Schmid Andreas, Grathwohl Dominik, Bültermann Dirk, Berg Aloys. Hematological indices and iron status in athletes of various sports and performances. Med Sci Sports Exerc. 2002 May;34(5):869–875. doi: 10.1097/00005768-200205000-00022. [DOI] [PubMed] [Google Scholar]
  30. Sullivan J. L. Iron therapy and cardiovascular disease. Kidney Int Suppl. 1999 Mar;69:S135–S137. doi: 10.1046/j.1523-1755.1999.055suppl.69135.x. [DOI] [PubMed] [Google Scholar]
  31. Van Wyck D. B. Iron management during recombinant human erythropoietin therapy. Am J Kidney Dis. 1989 Aug;14(2 Suppl 1):9–13. [PubMed] [Google Scholar]
  32. Walters G. O., Miller F. M., Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol. 1973 Oct;26(10):770–772. doi: 10.1136/jcp.26.10.770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wood W. G. A comparison of eleven commercial kits for the determination of serum ferritin levels. J Clin Chem Clin Biochem. 1981 Sep;19(9):947–952. doi: 10.1515/cclm.1981.19.9.947. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Sports Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES